“Behind the Buzz” Show: INmune Bio Inc. (NASDAQ: INMB) Corporate Overview

FinancialBuzz.com’s latest Behind the Buzz Show: Featuring Our Corporate Overview on INmune Bio Inc.

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro595), and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. 

Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF) estimated that there were 18 million new cancer cases worldwide. Among these 18 million, 9.5 million were men and 8.5 million were women, while the most commonly diagnosed cancers were lung, breast, and colorectal. In particular, the top three diagnosed cancers accounted for over a third of total global cases. Most cases of cancer result from risk factors such as poor diet, nutrition, and physical condition. However, in some instances, cancer can be caused by hereditary factors such as genetics or environmental impacts. The WCRF mentioned that roughly 40% of cancer cases in 2018 could have been prevented if patients had a more well-rounded diet. Nonetheless, the number of cases is gradually rising, prompting pharmaceutical and biotechnology companies to develop innovative treatments. The cancer treatment market is a large sector due to the various methods and techniques companies choose to employ. For instance, chemotherapy is one of the most popular cancer treatments that uses anti-cancer drugs to either cure cancer, prolong life expectancy, or reduce symptoms. On the other hand, radiotherapy is another popular treatment that is aimed at controlling or eliminating malignant cells. Notably, immunotherapies have also become increasingly popular among cancer patients. Immunotherapy harnesses the patient’s immune system in order to fight against the cancer. Additionally, immunotherapy also helps the body fight against other infections and diseases. And according to data compiled by Grand View Research, the cancer immunotherapy market is projected to reach USD 126.9 Billion by 2026 while exhibiting a CAGR of 9.6% during the forecast period. 

Immunotherapy can be used to treat other diseases such as Alzheimer’s, however, it is most commonly associated with cancer treatment. Immunotherapy works by boosting the immune system, which allows the body to detect and destroy abnormal cells. Furthermore, the therapy also prevents and curbs the growth of other cancers from developing. There are several types of immunotherapies such as immune checkpoint inhibitors, T-cell transfer therapy, monoclonal antibodies, vaccines, and immune system modulators, according to the National Cancer Institute. Vaccines and T-cell transfer therapy focus on boosting the immune system and the T-cell’s ability to fight against cancer. On the other hand, immune checkpoint inhibitors are drugs used to block immune checkpoints, which allows immune cells to better respond to cancer cells. Additionally, monoclonal antibodies are proteins created to bind to specific targets on the cancer cells themselves. In some instances, monoclonal antibodies will mark cancer cells, allowing the immune system to better detect and ultimately destroy them. Although immunotherapy is not as popular as chemotherapy, radiotherapy, or surgery, it is becoming an increasingly popular cancer treatment method among patients. “In 2018, there were over 900 new cancer immunotherapies in development, with over 5,000 clinical trials investigating these agents and more than half a million patients being treated with these agents,” said Leonard H. Calabrese, DO, Vice Chairman of rheumatic and immunologic disease, at the Cleveland Clinic at the Seventh Annual Basic and Clinical Immunology for the Busy Clinician symposium. “Immunotherapy is now a pillar of cancer treatment — it is now ensconced as a part of this therapy.”

For more information, please visit: INmune Bio, Inc.

For more corporate news on INmune Bio, Inc., check out Behind the Buzz

About Behind the Buzz: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Behind the Buzz looks to become a leader in corporate video news dissemination. Behind the Buzz is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

2 Comments
  1. Ross Gerber 3 weeks ago
    Reply

    being able to specifically target these malignant cells will help evolve technology further to deal with detrimental diseases such as cancer.

  2. Zack Clayton 3 weeks ago
    Reply

    may have bottomed out since falling from May highs. I may enter if it holds about $6 for atleast a week.

Leave a Comment

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For inmune bio inc., financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by world wide holdings. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.